DUBLIN, October 28, 2011 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to September 30, 2011.
Financial Highlights Q3 2011(1) Product sales $1,018 million +28% Total revenues $1,086 million +24% Non GAAP operating income $341 million +15% US GAAP operating income $255 million +64% Non GAAP diluted earnings per ADS $1.28 +10% US GAAP diluted earnings per ADS $1.02 +96% Non GAAP cash generation $296 million +9% Non GAAP free cash flow $138 million +56% US GAAP net cash provided by operating activities $179 million +26%
(1) Percentages compare to equivalent period in 2010.
The Non GAAP financial measures included within this release are explained on page 24, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 19 - 23.
Angus Russell, Chief Executive Officer, commented:
"Shire has delivered another strong set of quarterly results. Total product sales were up 28% to $1,018 million, with our newly acquired regenerative medicine product, DERMAGRAFT for Diabetic Foot Ulcers, contributing sales of $50 million in the quarter. We're on track to deliver significant 2011 earnings growth.
Sales of our rare disease treatments were very strong: with VPRIV up 31% and REPLAGAL up 40% versus the same quarter in 2010. FIRAZYR, our self-administered treatment for acute attacks of Hereditary Angioedema, was approved by the FDA in August and launched just a few weeks ago; initial demand from patients has been positive. This week we have also initiated a rolling Biologics License Application for REPLAGAL in the US, designated Fast Track by the FDA.
The US ADHD market continues to grow and with a strong 'back to school' season, our portfolio of treatments has gained sha
|SOURCE Shire plc|
Copyright©2010 PR Newswire.
All rights reserved